Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dezocine + midazolam is a combination of two pharmaceutical agents used primarily for procedural sedation and analgesia, especially in gastrointestinal endoscopy. Dezocine is an opioid analgesic with mixed agonist/antagonist activity at opioid receptors (μ-agonist, κ-antagonist), providing effective pain relief with a relatively low risk of addiction. Midazolam is a benzodiazepine that acts as a positive allosteric modulator at the GABA-A receptor, producing sedative, anxiolytic, amnestic, and muscle relaxant effects but limited intrinsic analgesia. When combined, these drugs offer both sedation (from midazolam) and analgesia (from dezocine), resulting in improved patient comfort during procedures compared to either agent alone or standard endoscopy without sedation.[1][2][6][10] This combination has been shown to be safe and effective for moderate procedural sedation in adults undergoing colonoscopy or other digestive endoscopic procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dezocine + midazolam.